RMB Capital Management LLC lowered its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 32.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,886 shares of the company’s stock after selling 10,142 shares during the quarter. RMB Capital Management LLC’s holdings in Ionis Pharmaceuticals were worth $1,342,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Whittier Trust Co. grew its holdings in Ionis Pharmaceuticals by 283.0% during the second quarter. Whittier Trust Co. now owns 383 shares of the company’s stock worth $25,000 after purchasing an additional 283 shares during the period. CWM LLC grew its holdings in Ionis Pharmaceuticals by 361.4% during the second quarter. CWM LLC now owns 406 shares of the company’s stock worth $26,000 after purchasing an additional 318 shares during the period. Ellis Investment Partners LLC bought a new position in Ionis Pharmaceuticals during the second quarter worth about $32,000. Advisory Services Network LLC grew its holdings in Ionis Pharmaceuticals by 38.5% during the second quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock worth $58,000 after purchasing an additional 252 shares during the period. Finally, LS Investment Advisors LLC bought a new position in Ionis Pharmaceuticals during the second quarter worth about $60,000. 89.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:IONS traded down $0.31 during trading on Tuesday, reaching $64.82. 243,965 shares of the stock were exchanged, compared to its average volume of 1,002,545. Ionis Pharmaceuticals Inc has a 12 month low of $43.27 and a 12 month high of $86.58. The firm has a market cap of $9.13 billion, a PE ratio of 21.90 and a beta of 1.97. The stock has a 50-day moving average price of $65.76 and a 200-day moving average price of $69.55. The company has a current ratio of 10.01, a quick ratio of 9.93 and a debt-to-equity ratio of 0.45.
A number of equities analysts recently commented on the company. Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Evercore ISI set a $76.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, August 7th. BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, July 24th. ValuEngine cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Finally, TheStreet cut Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $69.00.
In related news, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $70.25, for a total value of $702,500.00. Following the completion of the sale, the chief executive officer now directly owns 79,634 shares in the company, valued at $5,594,288.50. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total value of $1,573,440.00. Following the completion of the sale, the chairman now owns 79,634 shares of the company’s stock, valued at $5,695,423.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,210 shares of company stock valued at $3,244,934. Corporate insiders own 2.40% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Further Reading: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.